ПОИСК ПО САЙТУ 
поиск по ресурсному центру Medicines will be provided to Kazakh patients free of charge.
On February 1, the Ministry of Health of the Republic of Kazakhstan and the United Nations Development Programme signed an agreement making innovative drugs Sofosbuvir and Daclatasvir available for Kazakhstan patients with viral hepatitis. This information was presented by the press service of LLP “SC-Pharmacy” – the sole distributor for the procurement of medicines.
The signing ceremony was attended by the Permanent Representative of UNDP in Kazakhstan Norimasa Shimomura and the Minister of Health of the Republic of Kazakhstan Elzhan Birtanov.
Within the framework of the agreement it is planned to procure medications worth about 1.5 billion tenge ($ 4.65 million). “The medication is included in the WHO List of Essential Medicines. Thanks to the support of the United Nations Development Programme, we will be able to ensure the maximum possible coverage of Kazakhstani patients with modern treatment of viral hepatitis”, said Yelzhan Birtanov during the signing ceremony.
According to the Minister of Health of the Republic of Kazakhstan Elzhan Birtanov, the opportunity to procure medicines with the support of the UNDP opens access to the most modern and, to date, the most efficient treatment for viral hepatitis, which in most cases allows to eliminate the virus from the body.
“UNDP’s mandate is to increase human potential throughout life. We are convinced that a full and active life is impossible without wide access of people to modern medical services and medicines. In this regard, we hope that the implementation of this initiative will not only help reduce the incidence of hepatitis C, but also improve the quality of life of thousands of Kazakhstan citizens and their families”, noted UNDP Permanent Representative to Kazakhstan Norimasa Shimomura during the ceremony.
